{"denoms":[{"counts":[{"groupId":"BG000","value":"20"}],"units":"Participants"}],"groups":[{"description":"Ixazomib 4.0 mg given on days 1, 8 15, 22 of a 28 day cycle maximum of 6 cycles.\n\nIxazomib","id":"BG000","title":"Ixazomib"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.27","value":"70.91"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"Male"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"Female"}],"paramType":"NUMBER","title":"Sex/Gender, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"18"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"14"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"Up to 20 adult patients with confirmed diagnosis of relapsed/refractory multiple myeloma will receive Ixazomib."}